Rhythm Biosciences Ltd (ASX: RHY) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Rhythm Biosciences Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $193.07 million
P/E Ratio N/A
Dividend Yield N/A
Shares Outstanding 202.17 million
Earnings per share -0.030
Dividend per share N/A
Year To Date Return 9.71%
Earnings Yield N/A
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of May 24th 2021

Rhythm Biosciences Ltd (ASX: RHY)
Latest News

RHY ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Rhythm Biosciences Ltd

Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. Its product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. Geographically, the company operates only in Australia.

RHY Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
03 Aug 2021 $0.96 $-0.04 -4.02% 190,612 $1.00 $1.01 $0.96
02 Aug 2021 $1.00 $0.08 8.74% 284,593 $0.95 $1.02 $0.94
30 Jul 2021 $0.92 $-0.05 -5.15% 275,581 $0.96 $0.96 $0.92
27 Jul 2021 $0.97 $-0.01 -1.03% 148,005 $0.96 $0.98 $0.94
26 Jul 2021 $0.98 $0.04 4.28% 79,801 $0.96 $0.98 $0.95
23 Jul 2021 $0.94 $-0.01 -1.06% 270,149 $0.95 $0.95 $0.92
22 Jul 2021 $0.95 $-0.02 -2.07% 120,386 $0.98 $0.98 $0.95
21 Jul 2021 $0.97 $-0.04 -4.00% 121,033 $1.01 $1.02 $0.97
20 Jul 2021 $1.00 $-0.02 -1.96% 150,184 $1.04 $1.04 $0.98
19 Jul 2021 $1.02 $0.08 8.47% 324,897 $0.95 $1.02 $0.95
16 Jul 2021 $0.95 $0.05 5.59% 189,381 $0.90 $0.96 $0.89
15 Jul 2021 $0.90 $0.05 5.88% 414,724 $0.90 $0.91 $0.89
14 Jul 2021 $0.85 $0.01 1.18% 62,969 $0.85 $0.86 $0.84
13 Jul 2021 $0.85 $-0.02 -2.33% 92,519 $0.86 $0.87 $0.85
12 Jul 2021 $0.86 $0.00 0.00% 114,548 $0.86 $0.87 $0.85
09 Jul 2021 $0.86 $0.01 1.18% 68,033 $0.86 $0.87 $0.85
08 Jul 2021 $0.85 $-0.02 -2.30% 125,067 $0.87 $0.87 $0.85
07 Jul 2021 $0.87 $-0.03 -3.33% 125,622 $0.89 $0.89 $0.87
06 Jul 2021 $0.90 $0.00 0.00% 208,794 $0.90 $0.90 $0.88

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
20 Nov 2020 Trevor Lockett Issued 1 $300,000
Issue of options. As per announcement on 20/11/2020.
03 Sep 2020 Eduardo Vom Issued 416 $25,000
Rights issue.
03 Sep 2020 Eduardo Vom Issued 426 $25,559
Rights issue.
03 Sep 2020 Otto Buttula Issued 900 $54,000
Rights issue.
03 Sep 2020 Otto Buttula Issued 25 $1,500,000
Issue of securities.
03 Sep 2020 Louis (Lou) Panaccio Issued 300 $18,000
Rights issue.
03 Sep 2020 Trevor Lockett Issued 60 $3,600
Rights issue.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Otto Leslie Steven Buttula Non-Executive ChairmanNon-Executive Director Oct 2019
Mr Buttula has experience in investment research, funds management and information technology and has held directorships in a number of public companies. Mr Buttula's executive experience includes co-founder and CEO and Managing Director of IWL Limited, an online financial services company that listed on the ASX in 1999. Mr Buttula also founded and was Managing Director of Investors Mutual, prior to which he was a co-founder and director of Lonsdale Securities Limited. Following his completion of executive duties, Mr Buttula was Non-Executive Chairman of platform and stockbroking provider Investorfirst Limited and led the acquisition of HUB24 Limited (ASX: HUB). More recently, he served on the Board as a non-executive director and Head of Audit & Risk at Imugene Limited (ASX: IMU) between 2014 and 2016.
Mr Louis (Lou) James Panaccio Non-Executive Director Aug 2017
Mr Panaccio is a chartered accountant with management experience in business and healthcare services. He is currently on the boards of ASX listed companies Sonic Healthcare Limited, Genera Biosystems Limited and Avita Medical Limited.Mr Panaccio is also on the board of Unison Housing Limited.Mr Panaccio has more than 20 experience as a board member of both public and private, for profit and not for profit companies. Previously, Mr Panaccio was the CEO of Melbourne Pathology and Monash IVF, and also executive Chairman of Health Networks Australia.
Dr Trevor John Lockett Executive DirectorTechnical Director Jun 2017
Dr Lockett is a molecular biologist by trade,Dr Lockett received his PhD in biochemistry from the University of Adelaide and postdoctoral experience at the Rockefeller University in New York. With over 30 years of research experience, predominantly at the CSIRO, Trevor has led research efforts in the areas of prostate cancer gene therapy, colorectal cancer prevention and the promotion of gastrointestinal health. In his role as Theme Leader, Colorectal Cancer and Gut Health, Dr Lockett oversaw the research efforts leading to the technology that is to become ColoSTAT.
Mr Eduardo Vom Non-Executive Director Jun 2020
Mr Vom is a Co-Founder and Executive Director of Planet Innovation, a technology development and commercialisation company. He has over 20 years of experience in technology development and commercialisation in the biotech industry, having held leadership roles at cancer diagnostics manufacturer Vision BioSystems and molecular diagnostics company Genetic Technologies. He also currently serves as a non-executive director with privately owned health and wellbeing companies and is well known for his expertise in digital healthcare, management of multi discipline projects, business strategy and technology commercialisation.
Mr Adrien Michele Wing Company Secretary
-
Ms Pauline M Moffatt Joint Company Secretary Oct 2018
-
Mr Glenn Gilbert Chief Executive Officer
-
Glenn Gilbert Chief Executive Officer
-
Adrien Michele Wing Company Secretary
-
Pauline M Moffatt Joint Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Loumea Investment Pty Ltd 10,000,000 8.63%
Ferndale Securities Pty Ltd 6,500,000 5.61%
Northern Star Nominees Pty Ltd 4,500,000 3.88%
Rojo Nero Capital Pty Ltd 4,166,668 3.60%
Mrs Sarah Cameron 3,008,334 2.60%
Jawaf Enterprises Pty Ltd 3,000,000 2.59%
The Trust Company (Australia) Limited 2,684,500 2.32%
Commonwealth Scientific & Industrial Research Organisation 2,500,000 2.16%
Giokir Pty Ltd 2,125,000 1.83%
Mr Hsien Michael Soo 2,110,000 1.82%
Dc & Pc Holdings Pty Ltd 2,055,000 1.77%
Ms Natalie Louise Patterson 2,000,000 1.73%
Mowbrick Pte Ltd 1,650,000 1.42%
Newfound Investments Pty Ltd 1,500,000 1.29%
Shane Francis Tanner & Lisa Jane Wheeler 1,500,000 1.29%
E&W Nominee Pty Ltd 1,277,917 1.10%
Mr Daniel Eddington & Mrs Julie Eddington 1,250,000 1.08%
Sindel Nominees Pty Ltd 1,250,000 1.08%
Taycol Nominees Pty Ltd 1,233,750 1.06%
Ardroy Securities Pty Ltd 1,100,000 0.95%

Profile

since

Note